Abstract 1891
Background
Randomized clinical trials (RCTs) have shown that initiating breast cancer (BC) screening between ages 50 to 69 and continuing it for 10 years decreases BC mortality. None of the existing RCTs included women over 74 and all included few women aged 70-74, such that the 95% confidence interval (CI) ranged from preventing 32.1 deaths to causing 17.2 deaths. However, there is no RCT data on when a woman should stop receiving BC screening, yet an estimated 52% of women over 75 receive screening mammograms in the US. A future randomized trial to study when to stop screening may be infeasible and potentially unethical. We used insurance claims data to emulate a (hypothetical) target trial of the effect of continuing screening on BC mortality among Medicare beneficiaries aged 70-74 or 75-84 years.
Methods
We emulated a hypothetical trial using a population-based cohort study with 20% random sample of Medicare (1999-2008). We selected 1,058,013 Medicare beneficiaries aged 70 to 84 with a life expectancy of at least 10 years and no previous diagnosis of BC, and who received a BC screening. We compared the following two strategies: continuing annual screening vs. stopping screening mammograms. The main outcome was 8-year standardized risk of BC mortality by age group (70-74, 75-84). Estimates are standardized by baseline and time-varying variables.
Results
In the 70-74 age group, the estimated 8-year BC-specific death risk difference (95% CI) of continuing vs. stopping screening was -1.0 deaths per 1000 women (-2.3 to 0.1); hazard ratio 0.78 (0.63 to 0.95). In the 75-84 age group, the corresponding risk difference was 0.07 deaths per 1000 women (-0.93 to 1.3); hazard ratio 1.00 (0.83 to 1.19). The estimated 8-year risk of BC was 5.5% under the continue screening strategy (5.3% in the 70-74 age group, 5.8% in the 75-84 age group), and 3.9% under the stop screening strategy (3.9% in the 70-74 age group, 3.9% in the 75-84 age group).
Conclusions
Among women who have received at least one screening mammogram, we estimated that, compared with stopping BC screening, continuing screening past the age of 75 years results in no material difference in cancer-specific mortality over the following 8-year period. Our results in the age range of 70-74 match those of existing randomized clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
US National Institutes of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4900 - Molecular profiling and prognostic significance of TP53 mutations in Diffuse Large B Cell Lymphoma: identifying a high-risk subgroup
Presenter: Yuan-Kai Shi
Session: Poster Display session 3
Resources:
Abstract
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract